Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of many solid tumors, with limited progress made in the area of myeloid malignancies. The low mutational burden of acute myeloid leukemia (AML) is one potential reason behind the lack of activity of T-cell harnessing ICIs, particu...

Descripción completa

Detalles Bibliográficos
Autores principales: Abaza, Yasmin, Zeidan, Amer M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318025/
https://www.ncbi.nlm.nih.gov/pubmed/35883692
http://dx.doi.org/10.3390/cells11142249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318025/
https://www.ncbi.nlm.nih.gov/pubmed/35883692
http://dx.doi.org/10.3390/cells11142249

Ejemplares similares